Zacks Investment Research on MSN

Exelixis posts preliminary '25 results, issues '26 outlook

Exelixis, Inc. EXEL reported preliminary, unaudited financial results for fiscal year 2025, issued financial guidance for ...

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data ...

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated ...
Le Lézard

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Exelixis, Inc. today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis ...